[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655248":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":19,"studyPopulation":19,"armGroups":29,"interventions":39,"overallOfficials":19,"centralContacts":45,"locations":51,"responsibleParty":69,"collaborators":19,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":19,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":19,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":19,"overallStatus":54,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Anahuac University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":19},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Change in Montreal Cognitive Assessment (MoCA) Score","The total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance","Baseline, Week 12, and Week 26.",{"measure":14,"description":15,"timeFrame":12},"Change in Mini-Mental State Examination (MMSE) Score","The total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance.",{"measure":17,"description":18,"timeFrame":12},"Change in Memory Alteration Test (M@T) Score","The total score ranges from 0 to 50 points, with higher scores indicating better memory performance.",null,{"allocation":21,"interventionModel":22,"interventionModelDescription":19,"primaryPurpose":23,"observationalModel":19,"timePerspective":19,"maskingInfo":24},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":25,"maskingDescription":19,"whoMasked":26},"DOUBLE",[27,28],"PARTICIPANT","INVESTIGATOR",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"Synbiotic - Control","EXPERIMENTAL","Participants will initially receive the synbiotic intervention and subsequently cross over to the control intervention.",[35],"Dietary Supplement: Synbiotic (Lactobacillus acidophilus LA-5 and Agave Inulin)",{"label":37,"type":32,"description":33,"interventionNames":38},"Control - Synbiotic",[35],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":19},"DIETARY_SUPPLEMENT","Synbiotic (Lactobacillus acidophilus LA-5 and Agave Inulin)","Participants will receive 2 g of Lactobacillus acidophilus (4 × 10⁹ CFU) plus 7 g of agave inulin, combined with 20 g of a powder containing almond, cinnamon, vanilla, and oats, dissolved in water and administered once daily for 12 weeks.",[37,31],[46],{"name":47,"role":48,"phone":49,"phoneExt":19,"email":50},"Antonio Ibarra, PhD","CONTACT","52 5554197603","jose.ibarra@anahuac.mx",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Universidad Anahuac","RECRUITING","Huixquilucan","State of Mexico","52786","Mexico","MX",{"type":61,"coordinates":62},"Point",[63,64],-99.35016,19.35985,{"lat":64,"lon":63},[67],{"name":47,"role":48,"phone":68,"phoneExt":19,"email":50},"52 55 54197603",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Jose Juan Antonio Ibarra Arias","Principal Investigator","100655248","lactobacillus-acidophilus-and-inulin-for-cognitive-impairment-in-obesity-100655248",false,"NCT07810517","Lactobacillus Acidophilus and Inulin for Cognitive Impairment in Obesity","Effect of Lactobacillus Acidophilus Combined With Inulin on Cognitive Impairment in Patients With Obesity","Inclusion Criteria:\n\n* Adults aged 30 to 40 years.\n* Diagnosis of obesity for more than 10 years.\n* Presence of mild cognitive impairment, evaluated using cognitive assessment scales.\n* BMI ≥30 kg\u002Fm².\n* Body fat percentage ≥35% in women and ≥25% in men.\n* Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Advanced cognitive impairment.\n* Diseases associated with cognitive impairment, including Alzheimer's disease, cerebral ischemia, cerebrovascular events, severe traumatic brain injury, or motor deficits.\n* Antibiotic use during the 3 months prior to treatment.\n* Allergy to almonds or any component of the synbiotic or vehicle.\n* Consumption of probiotics or supplements and\u002For frequent intake of high-fiber or fermented foods.\n* Diagnosed gastrointestinal disorders, including irritable bowel syndrome or inflammatory bowel disease, that could influence study outcomes.\n* Diagnosis of type 2 diabetes mellitus.","ALL","30 Years","40 Years",{"count":84,"type":85},40,"ESTIMATED","INTERVENTIONAL",[88],"NA","This randomized crossover clinical trial aims to evaluate the effect of a synbiotic containing Lactobacillus acidophilus and inulin on cognitive function in adults with obesity and mild cognitive impairment. Forty participants aged 30-40 years will be randomly assigned to two groups. Participants will receive either the synbiotic intervention or a control preparation, followed by crossover to the alternate intervention. Cognitive function will be evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Memory Alteration Test (M@T). Fecal butyrate and Lactobacillus acidophilus, as well as serum inflammatory cytokines and BDNF, will also be assessed to explore potential mechanisms involving the gut-brain axis.",[91],"Obesity (Disorder)","2026-09-08",{"date":94,"type":95},"2026-09-10","ACTUAL",{"date":97,"type":85},"2026-11-01",{"date":99,"type":85},"2027-06-01",{"name":5,"class":6},1]